STEROID HORMONAL INDEPENDENCE OF HER-2/NEU MESSENGER-RNA EXPRESSION IN 4 HUMAN OVARIAN-CARCINOMA CELL-LINES

被引:18
作者
JONES, J
LAGASSE, LD
KARLAN, BY
机构
[1] CEDARS SINAI MED CTR,DEPT OBSTET & GYNECOL,DIV GYNECOL ONCOL,LOS ANGELES,CA 90048
[2] UNIV CALIF LOS ANGELES,CEDARS SINAI MED CTR,SCH MED,LOS ANGELES,CA 90048
关键词
D O I
10.1006/gyno.1994.1316
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Overexpression of HER-2/neu, a 185-kDa tyrosine kinase growth factor receptor, in human ovarian cancers has been correlated with a poor prognosis for survival of the disease. Previous studies have demonstrated that dexamethasone (Dex) induces a dose-dependent increase in HER-2/neu mRNA levels in the ovarian cancer cell line SK-OV-3 by stabilizing the HER-2/neu message. We extended these studies to test whether estrogen (Es), progesterone (Pr), and Dex were capable of regulating HER-2/neu mRNA levels in the human ovarian cancer cell lines NIH:OVCAR-3, SW 626, OVCA 433, and Caov-3. Southern blotting demonstrated that all four cell lines contained a single copy of the 12.5-kb HER-2/neu gene. Blotting techniques demonstrated low to barely detectable levels of HER-2/neu mRNA and protein in these cell lines. To determine whether steroids regulated HER-2/neu expression, all four ovarian cancer cell lines were cultured in the presence of 1 x 10(-7) M Es, Pr, or Dex and Northern blotting was completed. Unlike SK-OV-3 cells, the cell lines tested did not respond to the steroid treatments with alterations in their HER-2/neu mRNA levels. In conclusion, neither Es, Pr, nor Dex regulates HER-2/neu mRNA levels in NIH:OVCAR-3, SW 626, OVCA 433, and Caov-3 ovarian cancer cells. Future therapeutic manipulations of HER-2/neu should not involve hormonal intervention. (C) 1994 Academic Press, Inc.
引用
收藏
页码:421 / 426
页数:6
相关论文
共 28 条
  • [21] READ LD, 1990, CANCER RES, V50, P3947
  • [22] COMMON EPITHELIAL CANCER OF THE OVARY .1.
    RICHARDSON, GS
    SCULLY, RE
    NIKRUI, N
    NELSON, JH
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1985, 312 (07) : 415 - 424
  • [23] THE NEU ONCOGENE - AN ERB-B-RELATED GENE ENCODING A 185,000-MR TUMOR-ANTIGEN
    SCHECHTER, AL
    STERN, DF
    VAIDYANATHAN, L
    DECKER, SJ
    DREBIN, JA
    GREENE, MI
    WEINBERG, RA
    [J]. NATURE, 1984, 312 (5994) : 513 - 516
  • [24] MONOCLONAL-ANTIBODY THERAPY OF HUMAN CANCER - TAKING THE HER2 PROTOONCOGENE TO THE CLINIC
    SHEPARD, HM
    LEWIS, GD
    SARUP, JC
    FENDLY, BM
    MANEVAL, D
    MORDENTI, J
    FIGARI, I
    KOTTS, CE
    PALLADINO, MA
    ULLRICH, A
    SLAMON, D
    [J]. JOURNAL OF CLINICAL IMMUNOLOGY, 1991, 11 (03) : 117 - 127
  • [25] SLAMON DJ, 1989, CANCER CEL, V7, P371
  • [26] STUDIES OF THE HER-2/NEU PROTO-ONCOGENE IN HUMAN-BREAST AND OVARIAN-CANCER
    SLAMON, DJ
    GODOLPHIN, W
    JONES, LA
    HOLT, JA
    WONG, SG
    KEITH, DE
    LEVIN, WJ
    STUART, SG
    UDOVE, J
    ULLRICH, A
    PRESS, MF
    [J]. SCIENCE, 1989, 244 (4905) : 707 - 712
  • [27] ELECTROPHORETIC TRANSFER OF PROTEINS FROM POLYACRYLAMIDE GELS TO NITROCELLULOSE SHEETS - PROCEDURE AND SOME APPLICATIONS
    TOWBIN, H
    STAEHELIN, T
    GORDON, J
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1979, 76 (09) : 4350 - 4354
  • [28] ZHANG X, 1989, ONCOGENE, V4, P985